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Abstract 
 
The tumour suppressor gene PTEN, located at chromosome sub-band 10q23.3, encodes a 
dual specificity phosphatase that negatively regulates the phosphatidylinositol 3’-kinase 
(PI3K) / Akt-dependent cellular survival pathway. PTEN is frequently inactivated in 
many tumour types including glioblastoma, prostate and endometrial cancers. While 
initial studies reported that PTEN gene mutations were rare in colorectal cancer, more 
recent reports have shown an approximate 18% incidence of somatic PTEN mutations in 
colorectal tumours exhibiting microsatellite instability (MSI+). To verify the role of this 
gene in colorectal tumorigenesis, we analysed paired normal and tumour DNA from 41 
unselected primary sporadic colorectal cancers for PTEN inactivation by mutation and/or 
allelic loss. We now report PTEN gene mutations in 19.5% (8/41) of tumours and allele 
loss, including all or part of the PTEN gene, in a further 17% (7/41) of cases. Both PTEN 
alleles were affected in over half (9/15) of these cases. Using immunohistochemistry, we 
have further shown that all tumours harbouring PTEN alterations have either reduced or 
absent PTEN expression and this correlated strongly with later clinical stage of tumour at 
presentation (p=0.02). In contrast to previous reports, all but one of the tumours with 
PTEN gene mutations were microsatellite stable (MSI-), suggesting that PTEN is 
involved in a distinct pathway of colorectal tumorigenesis that is separate from the 
pathway of mismatch repair deficiency. This work therefore establishes the importance of 
PTEN in primary sporadic colorectal cancer. 
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Introduction 
 
Colorectal cancer (CRC) constitutes the second most common cause of cancer deaths in 
many Western countries. Colorectal carcinogenesis is a multistep process with tumours 
displaying considerable genetic heterogeneity. A number of genetic and epigenetic 
alterations resulting in the inactivation of tumour suppressor genes and/or the activation 
of oncogenes have been described (Chung, 2000; Ilyas et al., 1999). DNA mismatch 
repair deficiency, observed in most cases of the familial syndrome hereditary 
nonpolyposis colon cancer, occurs in 10-15% of sporadic colorectal cancers (Aaltonen et 
al., 1993; Ionov et al., 1993; Thibodeau et al., 1993). Some of these molecular changes, 
such as mismatch repair deficiency, have been shown to correlate with the pathological 
features of the tumour and clinical course of the disease (Elsaleh, 2001; Elsaleh et al., 
2001a; Elsaleh et al., 2001b; Elsaleh et al., 2000; Watanabe et al., 2001). The range of 
genetic alterations involved in colorectal carcinogenesis is incomplete and further key 
genes involved in the pathogenesis of CRC remain to be identified. 
The tumour suppressor gene PTEN (phosphatase and tensin homologue deleted on 
chromosome 10), also known as MMAC1 (mutated in multiple advanced cancers 1) and 
TEP1 (TGFβ-regulated and epithelial cell-enriched phosphatase 1), is located on 
chromosome sub-band 10q23.3. PTEN encodes a dual specificity phosphatase displaying 
homology to the cytoskeletal proteins tensin and auxilin (Li & Sun, 1997; Li et al., 1997; 
Steck et al., 1997). PTEN is a protein and lipid phosphatase whose major substrate is the 
second messenger phosphatidylinositol 3,4,5-triphosphate (PIP-3), produced by the 
activity of phosphoinositide 3-kinase (PI3K). An important downstream target of PI3K is 
protein kinase B (PKB)/Akt which controls cell proliferation and protects cells from 
apoptosis. The role of PTEN in this pathway is to keep levels of PIP-3 low. Loss of PTEN 
function results in increased PIP-3 concentration and consequent PKB/Akt 
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hyperactivation leading to protection from various apoptotic stimuli (Downward, 1998; 
Maehama & Dixon, 1998; Myers et al., 1998). PTEN is now known to function as a 
tumour suppressor through negative regulation of the PI3K/Akt pathway (Li et al., 1998; 
Stambolic et al., 1998; Wu et al., 1998) among other roles. 
PTEN was considered a good candidate for involvement in colorectal tumorigenesis 
for a number of reasons. First, allele loss close to the PTEN locus has been reported in 
30% of sporadic CRC (Frayling et al., 1997). Second, somatic mutations or deletions of 
PTEN have been observed in many other sporadic cancers including glioblastoma (Wang 
et al., 1997), prostate cancer (Cairns et al., 1997), melanoma (Guldberg et al., 1997; 
Whiteman et al., 2002) and endometrial cancer (Mutter et al., 2000), in which the 
presence of PTEN mutations has been found to be a prognostic indicator (Minaguchi et 
al., 2001). Third, germline mutations of PTEN are associated with the autosomal 
dominant Cowden and Bannayan-Zonana syndromes (Liaw et al., 1997; Marsh et al., 
1997; Marsh et al., 1999), characterised by multiple hamartomas of many tissues 
including the gastrointestinal tract. Cowden syndrome is also associated with an increased 
risk of breast, thyroid and endometrial neoplasia (Eng, 2000; Eng & Peacocke, 1998; 
(Marsh et al., 1998). Germline PTEN mutations have also been recently implicated in 
Proteus and Proteus-like syndromes (Smith et al., 2002; Zhou et al., 2001; Zhou et al., 
2000b). Finally, colon cancer has been described in Pten+/- chimeric mice (Di Cristofano 
et al., 1998) but is not a known component of Cowden syndrome (Eng, 2000), although 
rare Cowden individuals have been found to have colorectal cancers (Eng, unpublished 
observations). 
Initial reports of PTEN mutation screening in sporadic CRC found somatic mutations 
to be uncommon (Chang et al., 1999; Negoro et al., 2000; Okami et al., 1998; Wang et 
al., 1998). However, more recent analyses have reported a 17-19% incidence of PTEN 
mutations in microsatellite unstable (MSI+) colorectal tumours and concluded that PTEN 
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mutations could be selected for during tumorigenesis, but as a later event (Dicuonzo et 
al., 2001; Guanti et al., 2000; Shin et al., 2001; Zhou et al., 2002b). To verify the role of 
PTEN in sporadic CRC and to explore its role in MSI- tumours, we screened a series of 
41 unselected primary sporadic colorectal tumours for PTEN mutations and deletions. In 
contrast to previous studies, we report the detection of PTEN gene mutations in 19.5% of 
sporadic colorectal tumours, all but one of which were microsatellite stable (MSI-). 
Furthermore, all tumours with PTEN gene alterations (mutation and/or deletion) showed a 
reduction or absence of PTEN expression, and this correlated clinically with later stage of 
disease at diagnosis. 
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Results 
 
Tumour MSI status 
Seven of the 41 (17%) tumours exhibited microsatellite instability (MSI+). Two of these 
were of the MSI-L phenotype (CRC 23 and 42) and five were MSI-H (CRC 7, 17, 18, 46 
and 52) (Table 1). None of the tumours showing LOH at 10q23 were MSI+ and only one 
of the tumours with mutations was MSI+ (CRC 17). This tumour harboured two separate 
mutations in exon 8, affecting both alleles. The first mutation was a frameshift mutation 
caused by a deletion of 4 bp (ACTT) corresponding to nucleotides 955-958 of the PTEN 
mRNA sequence. The second was a missense mutation (N323K) caused by a base change 
(T→A) which effectively lengthened the (A)6 tract within exon 8 to (A)7. 
 
PTEN mutation screening 
Paired normal and tumour DNA samples from 41 unselected primary sporadic colorectal 
tumours were screened for mutations of the PTEN coding and flanking intronic sequences 
(Figure 1), as well as for allelic loss at the PTEN locus. Ten somatic PTEN mutations and 
one previously-reported germline polymorphism (Sato et al., 2002) were identified in 
8/41 (19.5%) patients (Figure 2). All sequence changes were confirmed by re-
amplification and sequence analysis of an independent PCR product. Only one of the 
mutations (del 955-958) has been previously described (Ali et al., 1999; Bonneau & 
Longy, 2000; Kurose et al., 1998; Lin et al., 1998; Rhei et al., 1997). Six tumours 
harboured two or more mutations of PTEN, affecting both alleles. One tumour (CRC 1) 
demonstrated loss of one allele with mutation of the remaining allele. Of the 8 tumours 
with PTEN mutations, two (CRC 2 and 37) harboured homozygous somatic changes with 
the remainder having heterozygous somatic changes (Table 1). 
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The ten somatic mutations were located in exons 1, 3, 5, 7 and 8 (Figure 2). Eight 
were missense, one was nonsense and one was a frameshift mutation caused by the 
deletion of 4 bp (ACTT) within the PTEN coding region in exon 8. This mutation was 
detected in two tumours (CRC 17 and CRC 48A) from unrelated patients. Five mutations 
occurred in exon 5 (K125E, K125X, E150Q, D153Y D153N), which encodes the 
phosphatase domain of the protein. Six missense mutations (K62R, Y65C, K125E, 
E150Q, D153Y, D153N) and one nonsense mutation (K125X) fell within the N-terminal 
phosphatase domain of the protein (residues 7-185). The K125E and K125X mutations lie 
in the core phosphatase motif HCXXGRXXR (residues 123-130). Two further missense 
mutations (V217A, N323K) occurred within the C-terminal domain (residues 186-351) of 
the protein. Representative sequences of somatic mutations are presented (Figure 3). 
Apart from the primary tumour, patient CRC 37 also had a coincident polyp removed 
at the time of surgery. The PTEN mutation observed in exon 5 (E150Q) in the carcinoma, 
was not seen in the matched polyp sample from the same patient. 
 
Loss of heterozygosity (LOH) at the PTEN locus 
Using an initial five polymorphic markers, allele loss at the PTEN locus was observed in 
8 of the 41 (19.5%) tumours (Figure 4). Two tumours (CRC 12 and 14) demonstrated 
apparent homozygous deletion of PTEN with decreased amplification intensity of marker 
alleles but constant reference (β-globin exon 2) amplification intensity. CRC 12 showed 
homozygous deletion of the two flanking markers (D10S579 and D10S541) with all 
intragenic markers being non-informative. Retention of both alleles at D10S1735 defined 
the deletion boundary between D10S541 and D10S1735. CRC 14 showed homozygous 
deletion at D10S579 and AFMa086wg9 with LOH at IVS8 +32 T/G and retention of both 
alleles at D10S541 and D10S1735. Retention of heterozygosity at D10S1687, defined the 
boundary of deletion between this marker and D10S579. CRC 1 demonstrated LOH at 
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two intragenic marker loci with mutation of the remaining PTEN allele. The remaining 
five tumours demonstrated LOH (hemizygous deletion) without mutation of the 
remaining PTEN allele (Figure 4). Combined PTEN mutation and deletion data shows 
that of the 15 tumours with PTEN alterations (7 with mutations only, 5 with hemizygous 
deletion, 2 with homozygous deletion and 1 with concurrent LOH and mutation), both 
alleles were affected in over half (9/15) of the cases. 
 
Tumour PTEN expression 
Immunohistochemical analysis of normal colonic epithelium showed that PTEN 
expression was predominantly cytoplasmic (++ immunoreactivity, n=41), with some 
normal to weak nuclear staining (++, n=15; +, n=26; Figure 5). Analysis of tumour 
sections containing normal cells, vascular endothelium (internal positive control) and 
tumour cells showed a reduction of cytoplasmic staining intensity in 19 tumours (46%) 
and a total absence of staining in 10 tumours (24%) (Table 2). All tumours harbouring 
alterations of the PTEN gene demonstrated a reduction or absence of cytoplasmic PTEN 
expression (Figure 5). PTEN expression was retained in 12/41 (29%) tumours, none of 
which harboured any PTEN gene alterations (Table 2). Tumours with suspected 
homozygous deletions including PTEN showed a corresponding absence of PTEN 
expression (-, n=2) while tumours with hemizygous PTEN deletion all showed a 
corresponding decrease in PTEN expression (+, n=5) (Figure 5). Interestingly, the 
homozygous deletion in CRC 12 (deleted at D10S579 and D10S541) must have included 
the PTEN gene as PTEN expression was absent. CRC 12 showed homozygous deletion of 
the two flanking markers (D10S579 and D10S541) with all intragenic markers being non-
informative 
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In addition, 12 tumours showed reduced or absent PTEN immunoreactivity in the 
absence of any PTEN genetic alteration suggesting a role for epigenetic factors affecting 
PTEN expression in these tumours (Figure 5). 
 
Clinicopathological correlations 
Clinical characteristics were compared according to MSI status, because of the known 
correlations of MSI with certain clinicopathological features. MSI+ tumours were 
associated with being right sided and occurring in patients with younger age (p=0.03). In 
the 34 MSI- tumours, there was a significant association between reduced or absent 
PTEN staining in the tumour and later tumour stage (p=0.02). This was consistent with 
the trend seen between reduced or absent staining and incidence of death from CRC (no 
deaths in the 10 patients with normal tumour staining but 6 deaths in the 18 patients with 
reduced or absent staining). This association did not reach statistical significance but 
follow-up times were relatively short. There was a trend towards MSI- tumours without 
PTEN mutation or deletion occurring on the left side of the colon, but there was no 
association with sex, age of the patient, or grade of the tumour. 
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Discussion 
 
This report demonstrates that the PTEN tumour suppressor is frequently altered in 
primary sporadic CRC. Structural PTEN abnormalities (mutation and/or deletion) were 
present in 37% of primary tumours and affected both alleles in over half of the cases. All 
but one of the tumours with PTEN mutations were microsatellite stable (MSI-). All 
tumours with structural PTEN abnormalities showed a reduction or absence of PTEN 
expression in the neoplastic cells, and, conversely, no tumours that retained PTEN 
staining harboured PTEN alterations. In contrast to MSI+ CRC, known to harbour 
somatic PTEN mutations, none of the mutations detected in MSI- CRC occurred in the 
coding mononucleotide tracts in exons 7 and 8 (Zhou et al., 2002a). This suggests that the 
PTEN gene is involved in a distinct pathway of colorectal tumorigenesis that is separate 
from the pathway of mismatch repair deficiency. Interestingly, CRC 37 harboured a 
homozygous somatic mutation (E150Q) that was not present in the matched polyp sample 
of the same patient and further suggests that PTEN mutation may be involved in CRC 
progression. 
Reduced or absent PTEN expression has previously been reported in 35% of MSI+ 
CRC, of which 15-20% were shown to have PTEN alterations (Zhou et al., 2002b). In 
contrast, reduced expression has previously been documented in only approximately 17% 
of MSI- tumours and no structural PTEN alterations were documented in these tumours 
(Taniyama et al., 2001; Zhou et al., 2002b). Complete absence of PTEN expression has 
not been previously reported in any MSI- (or MSI status unknown) colorectal cancer 
(Taniyama et al., 2001; Zhou et al., 2002b) and this is the first report to correlate reduced 
or absent PTEN expression with PTEN structural abnormalities in a significant number of 
MSI- CRC. 
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PTEN inactivation appears to occur through different mechanisms in different tumour 
types and more than one mechanism can co-exist within a single tumour type (Taniyama 
et al., 2001; Zhou et al., 2002b). In our series of sporadic CRC, PTEN inactivation, with 
consequent reduction or absence of PTEN expression, appeared to occur by three distinct 
mechanisms. First, structural biallelic inactivation, through mutation of both alleles, 
homozygous deletion or a combination of mutation and deletion, occurred in 22% of 
tumours, and accounted for over half of the cases in which PTEN alterations were 
detected. While structural biallelic inactivation is common in glioblastoma multiforme, 
cervical carcinoma and endometrial cancer (Duerr et al., 1998; Kong et al., 1997; Kurose 
et al., 2000; Mutter et al., 2001; Mutter et al., 2000; Zhou et al., 1999), it has not been 
previously observed in CRC.  
Second, monoallellic inactivation by mutation or hemizygous deletion of PTEN was 
found in a similar proportion (20%) of tumours in our series. Interestingly, hemizygous 
deletion led to reduced PTEN expression while monallelic mutation of PTEN led to either 
reduced or absent expression. It is possible that the remaining allele harbours a mutation 
occurring in a region of the gene not analysed in this study, or that epigenetic factors may 
be acting on the remaining allele. Interestingly, hemizygous PTEN knockout mouse 
models have demonstrated that loss of a single PTEN allele is sufficient for tumorigenesis 
(Di Cristofano et al., 1999; Di Cristofano et al., 1998; Podsypanina et al., 1999; Stambolic 
et al., 1998), and hemizygous deletion of PTEN appears to be common in some tumour 
types such as breast and prostate cancers (Feilotter et al., 1998; Singh et al., 1998). 
We also identified a third group of tumours with reduced or absent PTEN expression 
but without any detectable PTEN structural genetic alterations. It is postulated that PTEN 
may be inactivated by epigenetic mechanisms alone, suggesting that biallelic epigenetic 
silencing may also be a mechanism of PTEN inactivation in sporadic CRC. Biallelic 
epigenetic silencing is the predominant mechanism of PTEN inactivation in metastatic 
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melanoma (Zhou et al., 2000a) and occurs in a small subset of epithelial ovarian 
carcinomas (Salvesen et al., 2001; Zhou et al., 2000a). 
Mutations of the PTEN gene were detected in 19.5% of primary sporadic colorectal 
tumours (MSI-, n=7; MSI+, n=1). Nine novel, and one previously reported, mutations 
were detected in this study (Ali et al., 1999; Bonneau & Longy, 2000; Kurose et al., 1998; 
Lin et al., 1998; Rhei et al., 1997; Sato et al., 2002). While PTEN mutations have been 
reported in 17-19% of MSI+ CRC (Dicuonzo et al., 2001; Guanti et al., 2000; Shin et al., 
2001), they have not been previously documented in a significant proportion of MSI- 
tumours (Chang et al., 1999; Negoro et al., 2000; Okami et al., 1998; Wang et al., 1998). 
Our detection of a higher frequency of PTEN mutations in sporadic MSI- CRC, in 
contrast to previous reports, may be attributed to several factors. First, the technique of 
dideoxy fingerprinting (ddF) for mutation screening is known to be more sensitive and 
less dependent on the nature of the mutation, than single strand conformation 
polymorphism (SSCP) (Sarkar et al., 1992) used in all but one of the previous studies 
(Liu & Sommer, 1994). 
Furthermore, SSCP has been shown to be highly insensitive in detecting germline 
PTEN mutations in Proteus syndrome (0% detection rate) (Eng et al., 2001). Second, our 
study involved microdissection of tumour specimens to minimise contamination of 
normal tissue DNA. Third, there may be population differences in the incidence of PTEN 
mutations in CRC, similar to that observed in endometrial cancer (Maxwell et al., 2000). 
Exon 5, encoding the phosphatase domain of the protein, a region crucial for tumour 
suppressor function, appeared to be targeted with 50% of mutations occurring in this 
exon. Overall, the N-terminal phosphatase domain (residues 7-185) was the site of 6 
missense and one nonsense mutation, including the K125E and K125X mutations that lie 
within the core phosphatase motif of PTEN and are predicted to alter at least the lipid 
phosphatase activity essential for PTEN tumour suppressor function (Han et al., 2000; 
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Lee et al., 1999). Interestingly, codon 125, an invariant lysine residue, appears to be a 
target with two distinct mutations occurring at this site. Two missense (V217A, N323K) 
and one frameshift mutation were located within the C-terminal domain of the protein. 
This region is also essential for tumour suppressor function and partial or total absence of 
phosphatase activity has been demonstrated to result from amino acid changes outside the 
phosphatase domain (Georgescu et al., 1999; Han et al., 2000).  
The frameshift mutation (del ACTT 955-958) was observed as a heterozygous 
change in two tumours (CRC 17 and 48A) from unrelated patients. The deletion of 4 bp 
changes codon 319 to a termination codon leading to a truncated PTEN protein lacking 
predicted phosphorylation sites (specific tyrosine and/or serine residues) and the C-
terminal C2 domain that is important for phospholipid binding (Lee et al., 1999; Miller et 
al., 2002). Interestingly, one of the tumours harbouring this mutation was MSI+ (CRC 
17), whilst the other was MSI- (CRC 48A). This mutation has been previously reported in 
endometrial cancer (Kurose et al., 1998; Lin et al., 1998). Neither this nor the second 
mutation present in the MSI+ (N323K) tumour was typical of deficient mismatch repair, 
suggesting that the tumorigenic mechanism involving PTEN is independent from that of 
mismatch repair. 
Similar to the clinicopathological correlations now well established for MSI+ 
tumours (Elsaleh, 2001; Elsaleh et al., 2001a; Elsaleh et al., 2001b; Watanabe et al., 
2001), there may be certain characteristics associated with tumours harbouring PTEN 
alterations. The association between reduced or absent PTEN staining and later clinical 
stage at presentation is significant, and the trend towards abnormal PTEN staining and 
death from CRC, if verified in a large cohort, may translate into clinical use of PTEN 
expression to stratify prognostic groups, and hence, help to tailor adjuvant chemotherapy. 
The demonstration of PTEN mutations in 19.5% of sporadic colorectal tumours, and LOH 
in a similar proportion, with consequent reduction or abolition of PTEN expression in all 
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cases, redefines the role of this important tumour suppressor gene in sporadic CRC, 
particularly MSI- tumours. If subsequent in vitro functional studies confirm cellular 
dysfunction, PTEN may become a potential therapeutic target in CRC. In vitro and in vivo 
demonstration of enhanced sensitivity of PTEN-deficient tumours to inhibition of the 
FRAP/RAFT/TOR component of the P13K intracellular pathway by the rapamycin 
analogue CCI-779, has led to the postulate that such drugs may have clinical efficacy in 
human PTEN-deficient cancers (Neshat et al., 2001; Yu et al., 2001). Data presented here 
provides a molecular basis for the inclusion of patients with CRC in clinical trials of such 
novel anticancer agents. 
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Materials and methods 
 
Patients and tissue samples 
Samples of tumour, coincident polyps, matching blood and normal colon were collected 
prospectively with the informed consent of patients who underwent surgery in the South 
Western Sydney Area Health Service during the period 2000-2002. All samples are 
archived in the South Western Sydney Colorectal Tumour Bank. Consecutive unselected 
cases were examined except where insufficient material was available. Clinical details 
were obtained from the database of the Tumour Bank. The lack of a family history of 
colorectal cancer or other familial cancer syndrome was ascertained by detailed 
questionnaire. 
Forty-two primary colorectal cancers from 39 patients were studied. Two patients 
(CRC 30 and 48) had synchronous, distinct tumours (CRC 30A, CRC 30B and CRC 48A, 
CRC 48B) at the time of surgical resection and these were treated as separate entities. Of 
the 39 patients, 17 were females and 22 were males; mean age at diagnosis was 67 years 
(SD=10.9 years); and the mean duration of follow-up from date of diagnosis was 1.6 
years (SD=0.8 years). Nine patients (23.1%) had died, all from colorectal cancer, with a 
mean age at death of 72.0 years (SD=12.2 years). 
Of the 41 tumours, 23 (56.1 %) occurred on the right side of the colon (caecum, 
ascending colon or transverse colon) and 18 were left sided (descending colon, sigmoid 
colon or rectum). This distribution reflects the clinical practice of pre-operative 
chemoradiation for locally advanced rectal tumours, hence the lower availability of fresh 
tissue from left-sided tumours. Histologically, one tumour was purely mucinous. The 
remainder were adenocarcinomas, with three tumours showing areas of mucinous 
carcinoma and one displaying focal signet ring morphology. Clinical stage and 
histological grade were classified by standard criteria. Two tumours were grade 1, 31 
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tumours were grade 2 and 8 tumours were grade 3. Clinical staging at time of diagnosis 
was classified as Stage I-IV with 18 tumours being Stage I and II (early stage) and 23 
tumours being Stage III and IV (late stage). Stage I corresponds to the TNM staging of 
T1, N0, M0 or T2, N0, M0; Stage II corresponds to T3, N0, M0 or T4, N0, M0; Stage III 
corresponds to any T, N1, M0 or any T, N2, M0 and Stage IV corresponds to any T, any 
N, M1 (Beahrs, 1997). 
Fresh tissue samples of tumour and normal colonic epithelium (distant to the 
tumour site) were snap frozen in liquid nitrogen and stored at -80oC. Histological sections 
of a region immediately adjacent to the tumour sample taken for storage were processed 
for diagnostic purposes and reviewed by a dedicated histopathologist (CJH). For mutation 
screening, frozen sections (15 µm) were prepared from stored tumour specimens. The 
first, middle and last slides (5µm) were stained as reference slides. Manual 
microdissection was carried out on the unstained slides under low power light microscopy 
(20-40X) by scraping of individual cell populations with a 28-gauge needle. Normal cells 
adjacent to the tumour were collected separately. 
 
DNA extraction 
DNA was isolated from microdissected tumour cells and specimens of normal colonic 
mucosa using the RapidGene genomic DNA purification kit (Amresco) or the Qiagen 
DNA Mini system (QIAGEN), according to the manufacturer’s instructions. DNA was 
extracted from peripheral blood leukocytes using the DNA isolation kit for mammalian 
blood (Roche Molecular Biochemicals).  
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Analysis of MSI status 
Paired tumour and constitutional DNA samples were analysed using a panel of 10 
microsatellite markers as previously described (Kahnoski et al., 2003). Samples were 
classified as MSI-L (low level microsatellite instability) if instability was observed at 20-
40% of loci assayed or MSI-H (high level microsatellite instability) if instability was 
observed at over 40% of loci assayed (Boland et al., 1998). 
 
Amplification of the PTEN coding region 
DNA from paired normal and tumour tissue samples was screened for PTEN mutations 
by dideoxy fingerprinting (ddF). The entire PTEN coding and flanking intronic sequences 
were amplified by PCR. Primers used were as described (Guldberg et al., 1997), with the 
exception of exon 5 which was amplified into two overlapping segments (A and B) using 
the primers PTENEx5a-Fwd (5’-TATGCAACATTTCTAAAGTTACC-3’) with 
PTENEx5a-Rev (5’-GCACATATCATTACAGTTC-3’) and PTENEx5b-Fwd (5’-AATG 
GCTAAGTGAAGATGACAA-3’) with PTENEx5b-Rev (5’-AAGAAACCCAAAATCT 
GTTTTCC-3') respectively. PCR was carried out in a final volume of 50 µL containing 
25 ng DNA, 20 pmol each primer, 0.2 mM dNTPs, 1.5 mM MgCl2, 50 mM KCl, 10 mM 
Tris-HCl (pH 9.0) and 0.5 U Taq polymerase (Amersham-Pharmacia Biotech). An initial 
denaturation step (95 oC, 5 min) was followed by 34 cycles of denaturation (95 oC, 45 s), 
primer annealing (50-60 oC, 45 s) and extension (72 oC, 45 s). PCR was ended with a 
final extension (72 oC, 10 min) step. An aliquot of each PCR product was analysed on 2% 
agarose gels to check the efficiency of PCR. 
 
Dideoxy fingerprinting analysis  
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Following amplification, PCR products were purified using the JetQuick PCR product 
cleanup system (Genomed). Amplicons were eluted in 35 µL of TE buffer (10 mM Tris-
HCl, pH 8.0; 1 mM EDTA) and 5 µL was used to estimate DNA concentration by 
electrophoresis against known standards. Typically, 4 µL of purified PCR product was 
subjected to a cycle sequencing reaction using the Sequitherm Excel II system (Epicentre 
Technologies) with the appropriate forward PCR primer and a single ddNTP. The 
sequencing reactions were carried out in a final volume of 6 µL containing 20 pmol 
forward primer essentially as described by the manufacturer. Sequencing products were 
mixed with an equal volume of loading buffer (10 mM NaOH, 95% deionised formamide, 
0.05% bromophenol blue and 0.05% xylene cyanol), denatured at 95 oC for 5 min and 
quick chilled on ice. An aliquot (4 µL) was electrophoresed (12 W, 22 oC, 4.5 h) on 0.5 X 
MDE (Mutation Detection Enhancement: FMC BioProducts) gels. Products were 
visualised by autoradiography. Samples showing migration shifts were selected for 
sequencing analysis using the amplification primers. Samples were subjected to both 
manual (SequiTherm Excel II: Epicentre Technologies) and automated sequencing 
(Applied Biosystems ABI 377 at the Westmead Sequencing Facility or ABI 3700 at the 
Sydney University and Prince Alfred Macromolecular Analysis Centre (SUPAMAC), 
Australia). Products were sequenced in both directions and mutations verified on both 
DNA strands. Samples with sequence variations were re-amplified and re-sequenced from 
a second independent PCR product to ensure reproducibility of detected sequence 
changes. For those samples in which the mutation(s) could not be unambiguously 
identified by sequence analysis, the primary PCR product was cloned (TOPO TA 
Cloning, Invitrogen) and 10 clones were sequenced. 
 
Analysis of LOH at the PTEN locus  
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Allelic loss at the PTEN locus was determined using the markers D10S1687, D10S579, 
D10S541 and D10S1735, that flank the PTEN gene, as well as three intragenic markers: 
AFMa086wg9 (intron 2), IVS4 +109 ins/del TCTTA and IVS8 +32 T/G. Marker 
positions and primer sequences for D10S579, D10S541, D10S1735 and AFMa086wg9 
were obtained from the Whitehaed Institute for Biomedical Research/MIT Centre for 
Genome Research maps and contigs at http://www-genome.wi.mit.edu and from the 
Genome Database. Primers for the amplification of IVS4 +109 ins/del TCTTA and IVS8 
+32 T/G were as described by Zhou et al (Zhou et al., 2000a) and Hansen et al (Hansen et 
al., 2001) respectively. After amplification, the IVS4 +109 ins/del and IVS8 +32 T/G 
genotypes were determined by differential digestion of the respective PCR products with 
the restriction endonucleases AflII and HindII (Roche Molecular Biochemicals) 
respectively (Dahia et al., 1997; Zhou et al., 2000a). Digestion products were separated 
on 3% agarose gels.  
Each of the markers D10S1687, D10S579, D10S541, D10S1735 and AFMa086wg9 
were co-amplified with exon 2 of the β-globin gene that was used as an internal standard 
to monitor amplification efficiency. A 280 bp region containing exon 2, and part of the 
flanking intron 3, of the β-globin gene was amplified using the primers BGE2-Fwd (5’-
CTCTGCCTATTGGTCTATTTTCCC-3’) and BGE2-Rev (5’-GAAAACATCAAGGGT 
CCCATAGAC-3’). Amplification was performed in a final volume of 25 µl containing 
25 ng genomic DNA, 20 pmol each respective primer (forward primers were 5’-HEX 
labelled with the exception of BGE2-Fwd which had a 5’-FAM label), 0.2 mM dNTPs, 
50 mM KCl, 10 mM Tris-HCl (pH8.3), 1.5 mM MgCl2 and 0.5 U Taq polymerase 
(Amersham-Pharmacia Biotech). PCR was initiated by a 5 min denaturation (94 oC) 
followed by 28 cycles of denaturation (94 oC, 45 s), primer annealing (50-60 oC, 45 s) and 
extension (72 oC, 45 s). PCR cycling was ended with a 10 min extension (72 oC) step. The 
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products were checked by electrophoresis on 2% agarose gels. Fluorescently-labelled 
products were then electrophoresed on an Applied Biosystems ABI 3700 system 
(SUPAMAC, Australia). Analysis of peak signal areas, corresponding to fluorescence 
intensity, was carried out using the GeneScan 3.1 analysis software (Applied 
Biosystems). Ratios of signal intensities were calculated for the two alleles at each marker 
locus. Allele loss was defined according to the following formula: LOH index = 
(T2/T1)/(N2/N1), where T was the tumour sample, N was the matched normal sample, 1 
and 2 were the intensities of the smaller and larger alleles, respectively (Giraud et al., 
1997).  Loss of an allele was established if the ratio was < 0.67 or > 1.3.  
Initially, five markers were analysed (D10S579, AFMs086wg9, IVS4, IVS8, 
D10S541) in all samples. Those samples showing allele loss at the extreme centromeric 
or telomeric markers were analysed with a further two markers (D10S1687 and 
D10S1735) to define the deletion boundaries. Overall, samples were scored as showing 
LOH if allele loss was observed at two or more of the five initial marker loci analysed. 
 
Determination of the allelic distribution of individual mutations 
Where more than one mutation occurred in an individual exon, the particular exon was re-
amplified and cloned using the TOPO TA cloning system (Invitrogen). Where mutations 
occurred in more than one exon of the gene in the same tumour, RT-PCR amplification of 
a region encompassing all mutations was carried out and the RT-PCR product cloned 
using the same system. Ten clones were sequenced to determine the allelic distribution of 
detected mutations. 
 
RNA extraction and RT-PCR analysis 
Where necessary, total RNA was isolated from microdissected tumour cells using the 
High Pure RNA Tissue kit (Roche Molecular Biochemicals) according to the 
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manufacturer’s instructions. Total RNA was reverse transcribed and amplified using the 
Superscript One Step RT-PCR system (Gibco BRL) as described by the manufacturer. 
RT-PCR was used to amplify the complete PTEN open reading frame using the exonic 
primers PTENEx1-Fwd (5’-ATGACAGCCATCATCAAAGAG-3’) and PTENEx9-Rev 
(5’-GACTTTTGTAATTTGTGTATGC-3’). The RT-PCR products were subsequently 
purified, cloned and sequenced.  
 
PTEN Immunohistochemical analysis and scoring 
Histological stage and tumour grade was determined by a dedicated pathologist (CJH) 
and a paraffin block representative of each tumour was selected. Immunohistochemical 
staining was carried out on histological sections using the PTEN monoclonal antibody 
6H2.1 (Cascade Bioscience, USA). This antibody, raised against the last 100 C-terminal 
amino acids of human PTEN, has been used by various investigators (Gimm et al., 2000; 
Perren et al., 1999; Zhou et al., 2000a; Zhou et al., 2002b). Essentially, tissue sections (3 
µm) were deparaffinised by soaking in xylene and hydrated by passing through a graded 
series of ethanol. Antigen retrieval was carried out by incubation of slides for 40 min at 
99°C in target retrieval solution (DAKO). Endogenous peroxidase was quenched by 
soaking the slides in 3% hydrogen peroxide for 5 min.   
Automated immunohistochemical staining was carried out using a DAKO 
immunoautostainer (Universal Staining System). Slides were sequentially incubated with 
a dilution (1:300) of the PTEN primary antibody (Ab) clone 6H2.1, biotinylated 
secondary antibody (DAKO) and peroxidase-labelled streptavidin reagent (DAKO). All 
incubations were performed at room temperature. Finally, 3’-3’ diaminobenzidine 
(DAKO) was used as the coloured chromogen which gives a brown product. Slides were 
counterstained with Harris haematoxylin, mounted and viewed under a light microscope. 
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Vascular endothelium, present in all sections, served as an internal positive control to 
monitor variation and act as a reference for determining intensity of staining in each slide 
as previously described (Gimm et al., 2000; Perren et al., 1999; Zhou et al., 2000a; Zhou 
et al., 2002b). In addition to positive controls, negative controls were slides treated 
identically to the tumour sections with the exception that they were incubated with a 
negative control reagent (DAKO) instead of the primary PTEN (6H2.1) antibody. 
Four independent observers (CE, CDM, XW and CJH) reviewed the slides and 
determined the immunostaining patterns and staining intensities of all slides blindly (with 
no prior knowledge of PTEN gene alteration status). Scoring was concordant in over 95% 
of cases, and where opinions differed, slides were re-reviewed and a consensus score 
applied. Immunostaining intensity of the vascular endothelium was scored as ++. 
Immunostaining intensities (cytoplasmic and nuclear) in tumour and normal bowel were 
compared to the vascular endothelium present within each section. Staining intensities 
equal to that of vascular endothelium were scored as ++ (normal or retained); weak or 
decreased staining intensity as + (reduced); and no immunostaining as - (absent). Any 
immunostaining intensity stronger than that of vascular endothelium was operationally 
graded as +++ (increased).  
 
Statistical analyses 
Analyses were conducted for all tumours and for the subgroup of MSI- tumours. 
Continuous variables were compared using the t-test. Associations between categorical 
variables were determined by the chi square test or the Fisher exact test when subgroup 
numbers were low. All analyses were conducted using SAS version 8 (SAS Institute Inc. 
Cary, NC, USA). A p-value of ≤ 0.05 was taken as denoting statistical significance. 
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Table 1    Alterations of the PTEN gene and effect on PTEN expression in sporadic microsatellite 
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5 -ve - - A1 or A2 LOH Reduced 
6 -ve - - A1 or A2 LOH Reduced 
12 -ve - - A1 + A2 HDh Absent 
14 -ve - - A1 + A2 HD Absent 
17 +ve Del ACTT (955-8)i 
AAT→AAA 
















A1 + A2 
A1 or A2 
ROH Absent 
27 -ve - - A1 or A2 LOH Reduced 
34 -ve - - A1 or A2 LOH Reduced 
37 -ve GAG→CAGg E150Q A1 + A2 ROH Reduced 
45 -ve - - A1 or A2 LOH Reduced 
48A -ve Del ACTT (955-8)i Stop at 319 A1 or A2 ROH Absent 
aAffected PTEN allele(s) inferred from cloning, sequencing and LOH analysis. 
bLOH was determined from analysis of the flanking markers D10S579 and D10S541 as well as the 3 
intragenic markers AFMa086wg9, IVS4 +109 ins/del ACTT and IVS8 +32 G/T.  
cIndividual PTEN alleles have been arbitrarily named A1 and A2. 
dLoss of heterozygosity at two or more of the 5 marker loci. 
eHomozygous germline polymorphism. Numbering is relative to the translational start site (+1). 
fRetention of heterozygosity. 
gHomozygous somatic mutation. 
hSuspected homozygous deletion at two or more marker loci. 
iBase numbering is from the PTEN mRNA sequence with the translational start site as +1 
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Table 2    PTEN immunohistochemical analysis of primary sporadic colorectal tumours 
PTEN ABNORMALITY  TUMOUR PTEN EXPRESSIONa  
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LOH AT 10q 
  1 Allele 




























PTEN MUTATION + LOH 0 1 0 0 1 0 0 0 0 
NO PTEN ALTERATION 12 10 4 10 8 2 2 2 2 
TOTAL TUMOURS 12 19 10 10 17 7 2 2 3 
 
aChange in cytoplasmic PTEN antibody staining intensity 
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Legends to figures 
 
Figure 1  Dideoxy fingerprinting (ddF) analysis of PTEN. Autoradiographs of gels 
showing germline and somatic migration shifts (a-f). Those samples showing band shifts 
were chosen for sequence analysis. (a) germline shift observed in CRC 20 exon 1; 
Somatic shifts observed in: (b) CRC 3 exon 7; (c) CRC 48A exon 8; (d) CRC 17 exon 8; 
(e) CRC 2 exon 5 and (f) CRC 37 exon 5. The symbols used are: G, germline or 
constitutional DNA; T, tumour DNA; N, normal bowel DNA; A, DNA extracted from 
normal cells adjacent to the tumour.  
 
Figure 2  Mutations of the PTEN gene in primary sporadic colorectal cancer. Schematic 
representation of the PTEN gene showing the type and position of each detected sequence 
variation. The germline sequence changes (polymorphism) is presented below the bar and 
the somatic mutations above the bar. Heterozygous mutations are shown in plain type, 
homozygous mutations have been underlined and mutations detected more than once are 
indicated. 
 
Figure 3  Sequence analysis of novel PTEN somatic mutations. Samples showing 
migration shifts (a-e) were sequenced to determine the nature of the suspected mutation. 
(a) Biallelic mutation of PTEN in CRC 19. Two mutations (K62R and Y65C) were 
detected in exon 3 of CRC 19. The mutant sequence was cloned and each mutation was 
found to be located in a different clone suggesting that each mutation occurred on a 
different PTEN allele. (b) Heterozygous somatic mutation (D153Y) in CRC 3, exon 5; (c) 
heterozygous somatic mutation (V217A) in CRC 3 exon 7; (d) homozygous somatic 
mutation (E150Q) in CRC 37 exon 5; (e) homozygous somatic mutation (D153N) in CRC 
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2 exon 5. The symbols used are: G, germline or constitutional DNA; T, tumour DNA. 
The arrows indicate the position(s) of the sequence variation(s). 
 
Figure 4  Analysis of LOH at 10q23. (a) Schematic representation of the PTEN locus 
showing the microsatellite markers within and flanking the PTEN gene. The relative 
positions of markers are indicated. (b) Hemizygous deletion at the PTEN locus in CRC 1 
at D10S541 is shown in the two top panels. Amplification of the larger allele (T2) is 
reduced in the tumour compared to the germline (N2) DNA. Apparent homozygous 
deletion at the PTEN locus in CRC 12 at D10S579 is shown in the two lower panels. 
Amplification of both alleles (T1 and T2) is reduced in the tumour DNA compared to the 
germline or constitutional (N1 and N2) DNA with retention of comparable amplification 
intensity of the PCR amplification standard (BG) in the germline and tumour DNA. (c) 
The deletion status of each polymorphic marker and the respective patient are shown. The 
open circles represent the presence of two intact alleles, the half-shaded circles indicate 
LOH at the particular marker and the black circles indicate homozygous deletion of a 
marker. No symbol has been shown in the cases where a particular marker(s) was non-
informative. ND indicates that the analysis was not done. 
 
Figure 5  PTEN expression in primary sporadic colorectal tumours. Immunostaining of 
tumours was carried out using a monoclonal PTEN antibody (6H2.1) as described. PTEN 
expression is indicated by the brown chromogenic reaction. Tumours shown in B-I are 
MSI- and tumour J is MSI+. Arrows indicate the positively-staining vascular endothelial 
cells present in all sections. (a) adjacent normal colonic epithelium showing strong (++) 
cytoplasmic and nuclear PTEN expression; (b) Retention (++) of cytoplasmic expression 
with absence of structural PTEN alterations (CRC 38); (c) Reduced (+) PTEN expression 
with monoallelic PTEN mutation (CRC 1); (d) Reduced (+) expression with biallelic 
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PTEN mutation (CRC 19); (e) Reduced (+) expression with hemizygous PTEN deletion 
(CRC 45); (f) Absence (-) of PTEN expression and biallelic PTEN mutation (CRC 20); 
(g) and (h) Absent (-) PTEN expression and suspected homozygous deletion including 
PTEN (CRC 12 and 14); (i) Absent (-) PTEN expression without detectable PTEN 
structural alteration (CRC 13); (j) Absence (-) of PTEN expression with biallelic PTEN 
mutation in the MSI+ tumour CRC 17. 
